We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation against us that could have a material adverse effect on our business, operating results or financial condition.

The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, MA expiring in 2023, and it has a non-cancelable lease agreement for its manufacturing space in Boston and office space in Fort Worth, TX both expiring in 2025 with early termination available at the company’s discretion in 2023. Termination options were not included in the lease term for the Company’s existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.

As of March 31, 2022, operating lease assets were $781,917. The amount and the maturity of the Company’s operating lease liabilities as of March 31, 2022, are as follows:

	March 31, 2022
2022 (March 31 - December 31)	$	413,437
2023		411,142
2034		159,872
2025		67,981
2026		—
Thereafter		—
Total future minimum lease payments		1,052,432
Less imputed interest		188,862
Total operating lease liabilities	$	863,570
Included in the condensed consolidated balance sheet:
Current operating lease liabilities	$	410,497
Non-current operating lease liabilities		453,073
Total operating lease liabilities	$	863,570

For the three months ended March 31, 2022 and 2021, the total lease cost is comprised of the following amounts:

	For the Three Months Ended March 31,
	2022		2021
Operating lease expense		116,611		67,509
Short-term lease expense		1,950		23,409
Total lease expense	$	118,561	$	90,918

	March 31, 2022
Weighted-average remaining lease term (in years)		2.7
Weighted-average discount rate		20	%

For the three months ended March 31, 2022 and 2021, there were no customers which accounted for more than 10% of product revenues. For the three months ended March 31, 2022 and 2021, a U.S. insurance payer represented 34% and 26% of product revenues, respectively.

At March 31, 2022, one insurance company and its affiliates accounted for approximately 28% of accounts receivable. At March 31, 2021, one insurance company and their affiliates accounted for approximately 45% of accounts receivable.

For the three months ended March 31, 2022 and 2021, approximately 52% and 56% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively.